Abstract

Rowachol (Tillotts) is a mixture of monoterpenes intended for the dissolution of cholesterol gallstones, as an adjunct to the existing drugs chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA) whose use we discussed last month.¹ When combined with CDCA, Rowachol is claimed to dissolve stones in the common duct. This article assesses its efficacy both alone and in combination therapy.